Fortress Biotech, Inc.
NASDAQ Capital MarketTotal Valuation
Fortress Biotech, Inc. carries a market capitalization of 163.51M, placing it among publicly traded companies globally. Its enterprise value stands at -162.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 163.51M |
| Enterprise Value | -162.04M |
Share Statistics
Fortress Biotech, Inc. currently has 33.19M shares outstanding.
| Shares Outstanding | 33.19M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 0.11 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Fortress Biotech, Inc. maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.50, indicating elevated leverage, while an interest coverage ratio of -6.42 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.86 |
| Quick Ratio | 2.72 |
| Debt / Equity | 26.50 |
| Debt / EBITDA | -1.05 |
| Interest Coverage | -6.42 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 47.77 |
| Return on Invested Capital (ROIC) | -29.26 |
| Return on Capital Employed (ROCE) | -22.45 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.05 |
Taxes
Over the trailing twelve months, Fortress Biotech, Inc. has paid 4.34M in income taxes, reflecting an effective tax rate of 3.26.
| Income Tax | 4.34M |
| Effective Tax Rate | 3.26 |
Stock Price Statistics
Fortress Biotech, Inc.'s stock has gained approximately 147.2619% over the past 52 weeks. The 50-day moving average sits at 14.67, while the 200-day moving average is 10.78.
| Beta (5Y) | N/A |
| 52-Week Price Change | 147.2619% |
| 50-Day Moving Average | 14.67 |
| 200-Day Moving Average | 10.78 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -51.12M, while operating income came in at -55.81M.
| Revenue | 66.16M |
| Gross Profit | 43.81M |
| Operating Income | -55.81M |
| Pretax Income | 133.28M |
| Net Income | 127.77M |
| EBITDA | -51.12M |
| EBIT | -55.81M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Fortress Biotech, Inc. holds 255.84M in cash and equivalents against 53.63M in total debt, resulting in a net debt position of -216.46M. Total book value stands at -623.65M, with working capital of 192.09M providing operational flexibility.
| Cash & Cash Equivalents | 255.84M |
| Total Debt | 53.63M |
| Net Debt | -216.46M |
| Equity (Book Value) | -623.65M |
| Book Value Per Share | N/A |
| Working Capital | 192.09M |
Cash Flow
Fortress Biotech, Inc. produced 157.64M in operating cash flow over the past twelve months.
| Operating Cash Flow | 157.64M |
| Capital Expenditures | N/A |
| Free Cash Flow | 157.64M |
| FCF Per Share | N/A |
Margins
Fortress Biotech, Inc. operates with a gross margin of 66.22, reflecting its pricing power and cost economics. The operating margin of -84.36 and net profit margin of 193.12 provide insight into operational efficiency.
| Gross Margin | 66.22 |
| Operating Margin | -84.36 |
| Pretax Margin | 201.45 |
| Profit Margin | 193.12 |
| EBITDA Margin | -77.27 |
Dividends & Yields
The company's payout ratio of -6.65 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | -6.65 |
| Shareholder Yield | N/A |
| FCF Yield | N/A |
Scores
Fortress Biotech, Inc. posts an Altman Z-Score of -2.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.30 |